Annual report pursuant to Section 13 and 15(d)

Document And Entity Information

Document And Entity Information - USD ($)
$ in Billions
12 Months Ended
Jun. 30, 2019
Aug. 26, 2019
Dec. 31, 2018
Document Information [Line Items]      
Entity Registrant Name BIO-TECHNE Corp    
Entity Central Index Key 0000842023    
Trading Symbol tech    
Current Fiscal Year End Date --06-30    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Common Stock, Shares Outstanding (in shares)   38,063,504  
Entity Public Float     $ 5.5
Entity Shell Company false    
Document Type 10-K/A    
Document Period End Date Jun. 30, 2019    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag true    
Amendment Description This Amendment No. 1 on Form 10-K/A (“Amendment No. 1”) amends Bio-Techne Corporation’s (the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2019, as filed with the Securities and Exchange Commission (“SEC”) on August 28, 2019 (the “Original Filing”), solely to provide a revised version of KPMG LLP’s (“KPMG”) report, which corrects certain clerical items and a statement in the previously filed version that KPMG did not express an opinion on the Company’s internal controls over financial reporting, and makes a clerical correction in Item 9A to conform the name of the entity the Company acquired on June 4, 2019 to the Company’s consolidated financial statements. These changes to the filed version of KPMG's report included in the original filing do not affect KPMG's unqualified opinion on the Company's consolidated financial statements or KPMG's unqualified opinion on internal control over financial reporting included in the Original Filing and this Amendment No. 1. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 includes a new consent of KPMG (Exhibit 23.1), new certifications from the Company's principal executive officer (Exhibit 31.1) and principal financial officer (Exhibit 31.2) and new Section 1350 certifications (Exhibit 32.1 and 32.2) dated as of the date of filing of this Amendment No. 1. This Amendment No. 1 consists solely of the preceding cover page, this explanatory note, Part II., Item 8., “Consolidated Financial Statements and Supplementary Data,” in its entirety, Part IV., Item 15., “Exhibits and Financial Statement Schedules,” in its entirety, the signature page, and the new certifications from the Company’s principal executive officer and principal financial officer. Except as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information in any other item of the Original Filing. Amendment No. 1 speaks as of the date of the Original Filing, does not reflect events that may have occurred after the date of the Original Filing and does not modify or update in any way the disclosures made in the Original Filing, except as described above. Amendment No. 1 should be read in conjunction with the Original Filing and with the Company’s subsequent filings with the SEC.    
Title of 12(b) Security Common Stock